200 related articles for article (PubMed ID: 38594765)
1. Metallothionein-3 is a multifunctional driver that modulates the development of sorafenib-resistant phenotype in hepatocellular carcinoma cells.
Rodrigo MAM; Michalkova H; Jimenez AMJ; Petrlak F; Do T; Sivak L; Haddad Y; Kubickova P; de Los Rios V; Casal JI; Serrano-Macia M; Delgado TC; Boix L; Bruix J; Martinez Chantar ML; Adam V; Heger Z
Biomark Res; 2024 Apr; 12(1):38. PubMed ID: 38594765
[TBL] [Abstract][Full Text] [Related]
2. Metallothionein-3 promotes cisplatin chemoresistance remodelling in neuroblastoma.
Rodrigo MAM; Michalkova H; Strmiska V; Casar B; Crespo P; de Los Rios V; Ignacio Casal J; Haddad Y; Guran R; Eckschlager T; Pokorna P; Heger Z; Adam V
Sci Rep; 2021 Mar; 11(1):5496. PubMed ID: 33750814
[TBL] [Abstract][Full Text] [Related]
3. Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib.
Houessinon A; François C; Sauzay C; Louandre C; Mongelard G; Godin C; Bodeau S; Takahashi S; Saidak Z; Gutierrez L; Régimbeau JM; Barget N; Barbare JC; Ganne N; Chauffert B; Coriat R; Galmiche A
Mol Cancer; 2016 May; 15(1):38. PubMed ID: 27184800
[TBL] [Abstract][Full Text] [Related]
4. [Establishment and gene expression analysis of drug-resistant cell lines in hepatocellular carcinoma induced by sorafenib].
Ma B; Tian ZH; Qu L; Liu YX; Zhang H; Ding HR
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):207-213. PubMed ID: 32306000
[TBL] [Abstract][Full Text] [Related]
5. CRISPR/Cas9 screens unravel miR-3689a-3p regulating sorafenib resistance in hepatocellular carcinoma via suppressing CCS/SOD1-dependent mitochondrial oxidative stress.
Lu Y; Chan YT; Wu J; Feng Z; Yuan H; Li Q; Xing T; Xu L; Zhang C; Tan HY; Lee TK; Feng Y; Wang N
Drug Resist Updat; 2023 Nov; 71():101015. PubMed ID: 37924725
[TBL] [Abstract][Full Text] [Related]
6. Overriding sorafenib resistance via blocking lipid metabolism and Ras by sphingomyelin synthase 1 inhibition in hepatocellular carcinoma.
Lu H; Zhou L; Zuo H; Le W; Hu J; Zhang T; Li M; Yuan Y
Cancer Chemother Pharmacol; 2021 Feb; 87(2):217-228. PubMed ID: 33226447
[TBL] [Abstract][Full Text] [Related]
7. AKR1C3-dependent lipid droplet formation confers hepatocellular carcinoma cell adaptability to targeted therapy.
Wu C; Dai C; Li X; Sun M; Chu H; Xuan Q; Yin Y; Fang C; Yang F; Jiang Z; Lv Q; He K; Qu Y; Zhao B; Cai K; Zhang S; Sun R; Xu G; Zhang L; Sun S; Liu Y
Theranostics; 2022; 12(18):7681-7698. PubMed ID: 36451864
[No Abstract] [Full Text] [Related]
8. Involvement and Targeted Intervention of Mortalin-Regulated Proteome Phosphorylated-Modification in Hepatocellular Carcinoma.
Yang Y; Jin M; Dai Y; Shan W; Chen S; Cai R; Yang H; Tang L; Li L
Front Oncol; 2021; 11():687871. PubMed ID: 34395254
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib and FH535 in combination act synergistically on hepatocellular carcinoma by targeting cell bioenergetics and mitochondrial function.
Turcios L; Vilchez V; Acosta LF; Poyil P; Butterfield DA; Mitov M; Marti F; Gedaly R
Dig Liver Dis; 2017 Jun; 49(6):697-704. PubMed ID: 28179093
[TBL] [Abstract][Full Text] [Related]
10. Hydroxychloroquine (HCQ) Modulates Autophagy and Oxidative DNA Damage Stress in Hepatocellular Carcinoma to Overcome Sorafenib Resistance via TLR9/SOD1/hsa-miR-30a-5p/Beclin-1 Axis.
Chen MY; Yadav VK; Chu YC; Ong JR; Huang TY; Lee KF; Lee KH; Yeh CT; Lee WH
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34203465
[TBL] [Abstract][Full Text] [Related]
11. Bacterial metabolite butyrate in modulating sorafenib-targeted microRNAs to curtail its resistance in hepatocellular carcinoma.
Kumar M; Kaur R; Kanthaje S; Dhiman RK; Chakraborti A
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5823-5839. PubMed ID: 36583742
[TBL] [Abstract][Full Text] [Related]
12. Global transcriptomic study of circRNAs expression profile in sorafenib resistant hepatocellular carcinoma cells.
Wu MY; Tang YP; Liu JJ; Liang R; Luo XL
J Cancer; 2020; 11(10):2993-3001. PubMed ID: 32226514
[TBL] [Abstract][Full Text] [Related]
13. Torin2 overcomes sorafenib resistance via suppressing mTORC2-AKT-BAD pathway in hepatocellular carcinoma cells.
Hu YT; Shu ZY; Jiang JH; Xie QF; Zheng SS
Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):547-554. PubMed ID: 33051131
[TBL] [Abstract][Full Text] [Related]
14. Anterior gradient 2 induces resistance to sorafenib via endoplasmic reticulum stress regulation in hepatocellular carcinoma.
Tsai HW; Chen YL; Wang CI; Hsieh CC; Lin YH; Chu PM; Wu YH; Huang YC; Chen CY
Cancer Cell Int; 2023 Mar; 23(1):42. PubMed ID: 36899352
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide and sorafenib combination therapy for human hepatocellular carcinoma functions via up-regulation of TNF-related apoptosis-inducing ligand.
Wang L; Min Z; Wang X; Hu M; Song D; Ren Z; Cheng Y; Wang Y
Oncol Lett; 2018 Sep; 16(3):3341-3350. PubMed ID: 30127933
[TBL] [Abstract][Full Text] [Related]
16. The lncRNA lnc-TSI antagonizes sorafenib resistance in hepatocellular carcinoma via downregulating miR-4726-5p expression and upregulating KCNMA1 expression.
Chen F; Jiang J; Liu D; Li H; Dong L; Song Y; Zhang Y; Wang J; Qin Y; Zhao G
J Mol Histol; 2024 Feb; 55(1):83-96. PubMed ID: 38165571
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of PD-L1 expression promotes epithelial-to-mesenchymal transition in sorafenib-resistant hepatocellular carcinoma cells.
Xu GL; Ni CF; Liang HS; Xu YH; Wang WS; Shen J; Li MM; Zhu XL
Gastroenterol Rep (Oxf); 2020 Oct; 8(5):390-398. PubMed ID: 33163195
[TBL] [Abstract][Full Text] [Related]
18. LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription.
Lin Z; Xia S; Liang Y; Ji L; Pan Y; Jiang S; Wan Z; Tao L; Chen J; Lin C; Liang X; Xu J; Cai X
Theranostics; 2020; 10(19):8834-8850. PubMed ID: 32754282
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-138-1-3p sensitizes sorafenib to hepatocellular carcinoma by targeting PAK5 mediated β-catenin/ABCB1 signaling pathway.
Li TT; Mou J; Pan YJ; Huo FC; Du WQ; Liang J; Wang Y; Zhang LS; Pei DS
J Biomed Sci; 2021 Aug; 28(1):56. PubMed ID: 34340705
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular Carcinoma.
Hashiba T; Yamashita T; Okada H; Nio K; Hayashi T; Asahina Y; Hayashi T; Terashima T; Iida N; Takatori H; Shimakami T; Kawaguchi K; Arai K; Sakai Y; Yamashita T; Mizukoshi E; Takamura H; Ohta T; Honda M; Kaneko S
Cell Mol Gastroenterol Hepatol; 2020; 10(2):269-285. PubMed ID: 32169577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
